Article
The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.
The pharmacogenomics journal - 1 Apr 2015
de Jonge H, Elens L, de Loor H, van Schaik R H, Kuypers D R J
Abstract excerpt
Tacrolimus, a dual substrate of CYP3A4 and CYP3A5 has a narrow therapeutic index and is characterized by high between-subject variability in oral bioavailability. This study investigated the effects of the recently described CYP3A4*22 intron 6 C>T single nucleotide polymorphism on in vivo CYP3A4 activity as measured by midazolam (MDZ) clearance and tacrolimus pharmacokinetics in two cohorts of renal allograft...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.